SalaryGuide
AboutPricingFor Employers

Marketing jobs

4 marketing jobs

Regeneron logo
6 days ago

Director, HCP Marketing - Dermatology

Regeneron

Sleepy Hollow, NY (Unknown)$183K/yr – $305K/yr
Regeneron logo
6 days ago

Director, Global Commercial Planning & Strategy (Rare Disease)

Regeneron

USA (Unknown)$183K/yr – $305K/yr
Regeneron logo
7 days ago

Director, Market Access Analytics

Regeneron

Sleepy Hollow, NY (Unknown)$183K/yr – $305K/yr
Regeneron logo
2 months ago

Manager, Ophthalmology Marketing

Regeneron

Sleepy Hollow, NY (Unknown)$115K/yr – $187K/yr

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

4 jobs
Regeneron logo

Director, HCP Marketing - Dermatology

Regeneron

Sleepy Hollow, NY (Unknown)

$183K/yr - $305K/yrIn-houseSenior level12+ years exp.
6 days ago
Regeneron logo

Director, Global Commercial Planning & Strategy (Rare Disease)

Regeneron

USA (Unknown)

$183K/yr - $305K/yrIn-houseDirector/executive12+ years exp.
6 days ago
Regeneron logo

Director, Market Access Analytics

Regeneron

Sleepy Hollow, NY (Unknown)

$183K/yr - $305K/yrIn-houseDirector/executive12+ years exp.
7 days ago
Regeneron logo

Manager, Ophthalmology Marketing

Regeneron

Sleepy Hollow, NY (Unknown)

$115K/yr - $187K/yrIn-houseManager3+ years exp.
2 months ago
Regeneron logo
Regeneron

Director, HCP Marketing - Dermatology

Sleepy Hollow, NY (Unknown)

$183K/yr – $305K/yrSenior Level12+ years exp

Posted 6 days ago

Top 1% of applicants do these two things.

The other 99% submit and hope. You're about to do something different.

Job Summary

Owns the HCP atopic dermatitis marketing strategy and drives cross-functional, alliance-driven programs to deliver compliant, high-impact campaigns.

  • Lead HCP atopic dermatitis marketing strategy and integrate with the brand
  • Coordinate cross-functional and alliance partnerships across key stakeholders
  • Manage programs, budgets, timelines, and compliance to deliver impactful campaigns

Job Description

Responsibilities

  • Leading the HCP marketing strategy for atopic dermatitis, ensuring full integration with the broader brand strategy.
  • Acting as a key advocate for the Dermatology strategy, clearly articulating priorities and ensuring alignment across Regeneron, Sanofi, and other critical stakeholders.
  • Overseeing the development of HCP promotion strategies, messages, and tactical campaigns tailored to Dermatologists and Advanced Practice Providers.
  • Building and deploying a competitive market strategy that proactively addresses evolving competitors and market dynamics.
  • Driving strong cross-functional and alliance collaboration, partnering with Sales, Medical Affairs, TLLs, Market Research, Market Access, Regulatory, Legal, Clinical, and HEOR to deliver cohesive, compliant, and impactful initiatives.
  • Ensuring all marketing programs comply with corporate policies, regulatory/ethical frameworks, and alliance standards.
  • Managing marketing budgets, timelines, and deliverables to meet scope and performance expectations.

Requirements

  • Bachelor’s degree required; MBA strongly preferred.
  • 12+ years of progressive experience in the pharmaceutical/biotech industry or related field.
  • 8+ years of U.S. commercial experience in pharmaceutical/biotech marketing, product management, or related areas.
  • Dermatology and/or Immunology marketing and sales experience strongly preferred.
  • Demonstrated success in navigating complex alliance or co-promotion partnerships.
Regeneron logo

Regeneron

3.9 Glassdoor

At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work across our expanding global network to invent, develop and commercialize life-transforming medicines for people with serious diseases, we’re establishing new ways to think about science, manufacturing and commercialization. And new ways to think about health. Connect with us so we can learn more about you, and you can learn more about our biopharmaceutical medicines. And join us, as we build a future we believe in. Please visit www.regeneron.com/social-media-terms for information on how to engage with us on social media. An important note about privacy: Regeneron is committed to your privacy and will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or social media.

Founded in 1988
Tarrytown, New York, USA
16K employees (772 in marketing)
www.regeneron.com
73% recommend to a friend
88% CEO approval

Traffic Signals

Monthly Visitors
355.2K
Monthly Google Ads Budget
$56.8K
Traffic Source Mix
Search
40.8%
Direct
42.2%
Referral
9.5%
Social
6.3%
Paid
1%

Headcount Trend

Current headcount: ~16.5K

Marketing Team

Marketing Team Size
688 (4% of company)
Marketing Roles Posted (Last 30 Days)
3

Funding

Total Funding
$15.9M
Last Raise
$2M
Post IPO Equity, 2 years ago

Funding History

  • Jul 2024
    Post IPO Equity • $2M
  • Oct 2023
    Post IPO Equity • $5M
  • Aug 2016
    Post IPO Equity • $8.9M

Recent News

Regeneron's experimental therapy combo effective in untreated cancer patients
Dec 6, 2025 • Reuters
Regeneron inks gene editing deal with startup Tessera
Dec 1, 2025 • BioPharma Dive
Regeneron makes $150M bet on Tessera's rare disease gene writing prospect
Dec 1, 2025 • Fierce Biotech
Regeneron Makes $275M Gene Editing Play With Tessera Partnership Targeting AATD
Dec 1, 2025 • BioSpace
Regeneron Pharmaceuticals (REGN): Examining Valuation After Recent Share Price Momentum
Nov 25, 2025 • Yahoo Finance
Regeneron wins 2 Eylea nods, ramping up competition with Roche
Nov 20, 2025 • Fierce Pharma
Regeneron pledges $2B to convert former magazine factory into drug plant: NY governor
Nov 18, 2025 • Fierce Pharma
Governor Hochul Announces Regeneron to Invest More Than $2 Billion Into Saratoga County Facility, Creating 1,000 New Jobs
Nov 13, 2025 • Empire State Development (ESD) (.gov)
Regeneron to build $2 billion factory in Saratoga County, create 1,000 jobs
Nov 13, 2025 • Times Union
Gov. Hochul: Regeneron to invest more than $2B in new Spa City facility
Nov 13, 2025 • WRGB
Regeneron to expand into Saratoga Co. with new facility
Nov 13, 2025 • NEWS10 ABC
Regeneron (REGN): Revisiting Valuation After Recent 16% Share Price Rally
Nov 11, 2025 • Yahoo Finance
What Catalysts Are Driving the Changing Narrative for Regeneron?
Oct 30, 2025 • Yahoo Finance
Regeneron pledges more than $1B biobucks for ModeX multispecific antibodies
Oct 29, 2025 • Fierce Biotech
Regeneron Adds Fuel to Hot Healthcare Trade. Which Stocks Could Follow it Higher?
Oct 29, 2025 • Barron's
Regeneron receives another CRL for its Eylea 8 mg
Oct 29, 2025 • Ophthalmology Times
Regeneron tops quarterly estimates, plans to resubmit Eylea application
Oct 28, 2025 • Reuters
Regeneron's Earnings Took A Big Tax Hit, And Still Pounded Forecasts
Oct 28, 2025 • Investor's Business Daily
Regeneron (NASDAQ:REGN) Surprises With Strong Q3
Oct 28, 2025 • Yahoo Finance
A Look at Regeneron Pharmaceuticals’s Valuation Following Key European Regulatory Win for Libtayo
Oct 26, 2025 • Yahoo Finance
Regeneron Cans 2seventy-Acquired CAR T Candidate for Lymphoma in ‘Strategic’ Move
Oct 24, 2025 • BioSpace
Regeneron does 180 on 2seventy lymphoma CAR-T, halting study and nixing further development
Oct 23, 2025 • Fierce Biotech
Regeneron settles Eylea patent dispute with Celltrion, allowing another biosimilar to launch at end of 2026
Oct 22, 2025 • Fierce Pharma
Regeneron Pharmaceuticals, Inc. (REGN) Prepares for $83M Charge
Oct 13, 2025 • Yahoo Finance
Regeneron’s Gene Therapy DB-OTO Improves Speech Perception in Children With Otoferlin-Related Hearing Loss
Oct 13, 2025 • CGTLive®
Regeneron, with ‘game-changing’ new data, to seek approval of hearing loss gene therapy
Oct 12, 2025 • BioPharma Dive
Regeneron amplifies CHORD progression, sharing updated data on hearing loss gene therapy
Oct 12, 2025 • Fierce Biotech
Regeneron scores in adjuvant skin cancer | ApexOnco - Clinical Trials news and analysis
Oct 9, 2025 • Oncology Pipeline
Regeneron, needing a turnaround, gains new use for cancer drug
Oct 9, 2025 • BioPharma Dive
FDA approves Regeneron’s Libtayo for high-risk CSCC post-surgery
Oct 9, 2025 • Pharmaceutical Technology
US FDA expands use of Regeneron's Libtayo as add-on treatment for skin cancer
Oct 8, 2025 • Reuters
Regeneron (REGN) Highlights Benefits of Semaglutide and Trevogrumab in Obesity Management
Oct 2, 2025 • Yahoo Finance
Regeneron Pharmaceuticals Inc. (REGN) Reports Positive Results from Several Late-Stage Trials
Oct 1, 2025 • Yahoo Finance
6 FDA Decisions to Watch For in Q4
Sep 29, 2025 • BioSpace
Evkeeza® (evinacumab-dgnb) ANGPTL3 Antibody Approved in the U.S. for Children as Young as 1 Year Old with Ultra-Rare Form of High Cholesterol
Sep 29, 2025 • BioSpace
Regeneron announces U.S. FDA approved Evkeeza ANGPTL3 antibody
Sep 26, 2025 • thefly.com
U.S. Food and Drug Administration Approves Evkeeza (Evkeeza-dgnb) ANGPTL3 Antibody Approved in the U.S. for Children as Young as Young as 1 Year Old with Ultra-Rare Form of High Cholesterol
Sep 26, 2025 • MarketScreener
Evkeeza® (evinacumab-dgnb) ANGPTL3 Antibody Approved in the U.S. for Children as Young as 1 Year Old with Ultra-Rare Form of High Cholesterol
Sep 26, 2025 • Regeneron Pharmaceuticals, Inc.
COPD is still less likely than heart disease or lung cancer to be viewed as a leading cause of death
Sep 26, 2025 • EIN Presswire
FDA Expands Use Of Regeneron's Evkeeza To Infants With Rare Cholesterol Disorder
Sep 26, 2025 • Benzinga.com
Rheumatoid Arthritis Therapeutics Market Trends Analysis Report 2025-2033 by Molecule (Pharmaceuticals, Biopharmaceuticals), by Sales Channel (Prescription, Over-the-Counter)
Sep 26, 2025 • Research and Markets
Evkeeza® (evinacumab-dgnb) ANGPTL3 Antibody Approved in the U.S. for Children as Young as 1 Year Old with Ultra-Rare Form of High Cholesterol
Sep 26, 2025 • MarketScreener
Sanofi and Regeneron’s Dupixent receives CHMP recommendation for chronic spontaneous urticaria
Sep 26, 2025 • Pharmafile
Why Regeneron (REGN) Stock Is Down Today
Sep 23, 2025 • Yahoo Finance
US FDA declines to approve Scholar Rock’s muscle weakness drug; shares fall
Sep 23, 2025 • Investing.com
FDA rejects Scholar Rock's SMA drug, citing issues at Novo's Catalent Indiana site
Sep 23, 2025 • FiercePharma
Sanofi and Regeneron’s Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion
Sep 23, 2025 • PharmiWeb
Scholar Rock's Spinal Muscular Atrophy Drug Faces FDA Delay Over Catalent Indiana Inspection
Sep 23, 2025 • Benzinga.com
Labviva Kicks Off Smart Lab of the Future Tour
Sep 23, 2025 • Labviva
Much Maligned Manufacturing Site Trips Up Scholar Rock’s Spinal Muscular Atrophy Drug
Sep 23, 2025 • BioSpace
Wall Street Pauses For A Breather, Small Caps Soar: What's Moving Markets Tuesday?
Sep 23, 2025 • Benzinga.com
Dupixent® (dupilumab) to Treat Chronic Spontaneous Urticaria (CSU) Advances in EU with Positive CHMP Opinion
Sep 22, 2025 • BioSpace
FDA Delays Key Sanofi Multiple Sclerosis Drug Decision
Sep 22, 2025 • Benzinga.com
Regeneron, Sanofi announce CHMP opinion recommending Dupixent approval
Sep 22, 2025 • thefly.com
How the Narrative for Regeneron Has Shifted with Pipeline Wins and Analyst Optimism
Sep 20, 2025 • Yahoo Finance
Regeneron says blood cancer therapy shows 100% response rate in precancerous disorder study
Sep 19, 2025 • Reuters
Regeneron Pharmaceuticals (REGN) Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies
Sep 17, 2025 • Yahoo Finance
Regeneron drug reduces errant bone growth in ultra-rare skeletal condition
Sep 17, 2025 • statnews.com
Regeneron reports phase 3 win in ultrarare disease, bouncing back to spark race to FDA
Sep 17, 2025 • Fierce Biotech
Regeneron's rare bone disorder drug succeeds in late-stage trial
Sep 17, 2025 • Reuters
Regeneron announces primary endpoint met in Phase 3 OPTIMA trial
Sep 17, 2025 • thefly.com
Regeneron announces updated analyses from Phase 2 COURAGE trial
Sep 17, 2025 • thefly.com
Interleukin-13 Inhibitors Market Predicted to Surge During the Forecast Period (2025-2034) Due to Breakthrough Therapies in Atopic Dermatitis, Asthma, CRSwNP, and Others | DelveInsight
Sep 17, 2025 • PR Newswire
Interleukin-13 Inhibitors Market Predicted to Surge During the Forecast Period (2025-2034) Due to Breakthrough Therapies in Atopic Dermatitis, Asthma, CRSwNP, and Others | DelveInsight
Sep 17, 2025 • PR Newswire UK
Regeneron Pharmaceuticals, Inc. Announces Updated Analyses from the Ongoing Phase 2 Cloud Trial Investigating Novel Combination of Semaglutide (Glp-1 Receptor Agonist) and Trevogrumab (Anti-Myostatin)
Sep 17, 2025 • MarketScreener
Results from Phase 2 COURAGE Trial Demonstrating Potential to Improve Quality of GLP-1 receptor agonist-induced Weight Loss by Preserving Lean Mass, Presented at EASD
Sep 17, 2025 • MarketScreener
Regeneron, Elf Beauty, Eli Lilly
Sep 17, 2025 • Reuters
Regeneron Pharmaceuticals (REGN) Releases Results From EMPOWER-Lung 3 trial
Sep 16, 2025 • Yahoo Finance
Pozelimab and cemdisiran combo holds potential in MG market
Sep 16, 2025 • Pharma Letter
Senhwa Biosciences' CX-5461 Teams Up with Global PD-1 Leaders to Enter the Immunotherapy Arena, Targeting Multi-Billion Dollar Global Market
Sep 16, 2025 • PR Newswire
BMO Capital Maintains a Buy on Regeneron Pharmaceuticals (REGN)
Sep 15, 2025 • Yahoo Finance
Biotech Sector May Flip to Market Leader by Year-End
Sep 15, 2025 • MarketBeat
BMO Capital Maintains a Buy on Regeneron Pharmaceuticals (REGN), Sets a $640 PT
Sep 13, 2025 • Yahoo Finance
Phase III success for Regeneron signals pozelimab and cemdisiran’s entry into MG market
Sep 11, 2025 • Clinical Trials Arena
Beyond MariTide: Amgen Makes Portfolio Play Amid Scrutiny of Obesity Prospect
Sep 10, 2025 • BioSpace
Amgen, Kyowa Kirin Bolster Safety Profile for Atopic Dermatitis Hopeful
Sep 10, 2025 • BioSpace
Sandoz reaches agreement with Regeneron, resolving all patent litigation related to its US aflibercept biosimilar
Sep 9, 2025 • Sandoz
Regeneron’s cat and birch allergy mAbs score in Phase III trials
Sep 9, 2025 • Clinical Trials Arena
Regeneron’s Antibodies Block Cat and Birch Allergies With ‘Robust Activity’
Sep 9, 2025 • BioSpace
Sandoz and Regeneron reach agreement over biosimilar dispute
Sep 9, 2025 • Ophthalmology Times
Regeneron ends patent fight with Sandoz over Eylea biosimilar
Sep 9, 2025 • FirstWord Pharma
With settlement, Sandoz can launch its biosimilar to Regeneron's Eylea by end of 2026
Sep 9, 2025 • Fierce Pharma
REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Sep 9, 2025 • Bragar Eagel & Squire
Regeneron announces follow-up results on Phase 3 EMPOWER-Lung 3 trial
Sep 9, 2025 • thefly.com
With Asthma-Related ER Visits Increasing, AAFA Names 2025 Asthma Capitals
Sep 9, 2025 • Morningstar.com
Libtayo® (cemiplimab) Plus Chemotherapy Results at Five Years Reinforce Significant and Durable Improvements in Survival Outcomes for Advanced Non-small Cell Lung Cancer
Sep 9, 2025 • Regeneron Pharmaceuticals, Inc.
Sandoz reaches agreement with Regeneron over patent litigation
Sep 9, 2025 • thefly.com
Libtayo® (cemiplimab) Plus Chemotherapy Results at Five Years Reinforce Significant and Durable Improvements in Survival Outcomes for Advanced Non-small Cell Lung Cancer
Sep 9, 2025 • Morningstar.com
Regeneron at Morgan Stanley Conference: Strategic Pipeline Potential
Sep 8, 2025 • Investing.com
Regeneron's allergen-blocking antibodies score phase 3 wins against cat, pollen allergies
Sep 8, 2025 • Fierce Biotech
Regeneron Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies
Sep 8, 2025 • BioSpace
What's Happening With Regeneron Pharmaceuticals Stock On Monday?
Sep 8, 2025 • Benzinga.com
Regeneron Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies
Sep 8, 2025 • Morningstar.com
Regeneron Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies
Sep 8, 2025 • Regeneron Pharmaceuticals, Inc.
How Positive Phase 3 Cemdisiran Results at Regeneron (REGN) Have Changed Its Investment Story
Sep 6, 2025 • Yahoo Finance
'Several concerning observations': FDA sheds more light on reasons it rejected drugs
Sep 5, 2025 • FierceBiotech
Sanofi phase 3 eczema win falls short of analyst expectations
Sep 4, 2025 • FierceBiotech
Merck KGaA names new R&D chief as it doubles down on Africa growth
Sep 3, 2025 • Pharma Letter
Merck names new R&D chief for healthcare business
Sep 3, 2025 • pharmaphorum
Evercore ISI Maintains a Buy on Regeneron Pharmaceuticals (REGN) With a $750 PT
Sep 2, 2025 • Yahoo Finance